Author

Marc Ferrante

TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Marc Ferrante  et al.

TREATMENT PATTERNS OF COMPLEX PERIANAL FISTULA IN CROHN'S DISEASE IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN: THE PREFACE STUDY, A RETROSPECTIVE CHART REVIEW
TREATMENT PATTERNS OF COMPLEX PERIANAL FISTULA IN CROHN'S DISEASE IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN: THE PREFACE STUDY, A RETROSPECTIVE CHART REVIEW

Marc Ferrante  et al.

EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY
EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

Revolutionizing the treatment landscape in Crohn’s disease: How IL-23 and JAK inhibitors are changing the rhythm (AbbVie) (Complete Session)
Revolutionizing the treatment landscape in Crohn’s disease: How IL-23 and JAK inhibitors are changing the rhythm (AbbVie) (Complete Session)

Marc Ferrante  et al.

EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Gazing into the Crystal Ball: Current and Future Perspectives for Crohn’s Disease Complications (Boehringer Ingelheim)
Gazing into the Crystal Ball: Current and Future Perspectives for Crohn’s Disease Complications (Boehringer Ingelheim)

Marc Ferrante  et al.

CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS
CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS

Marc Ferrante  et al.

What I regretted most in treatment of fistulising ileal Crohn's disease
What I regretted most in treatment of fistulising ileal Crohn's disease

Marc Ferrante  et al.

A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES
A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

PRIMARY STUDY RESULTS FROM GO OBSERVE: A REAL-WORLD EUROPEAN PROSPECTIVE SINGLE-ARM OBSERVATIONAL COHORT STUDY OF PATIENT-REPORTED CONTINUOUS CLINICAL RESPONSE TO GOLIMUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
PRIMARY STUDY RESULTS FROM GO OBSERVE: A REAL-WORLD EUROPEAN PROSPECTIVE SINGLE-ARM OBSERVATIONAL COHORT STUDY OF PATIENT-REPORTED CONTINUOUS CLINICAL RESPONSE TO GOLIMUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Marc Ferrante  et al.

EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Marc Ferrante  et al.

VEDOLIZUMAB IS ASSOCIATED WITH STEROID-FREE CLINICAL REMISSION AND DISCONTINUATION-FREE SURVIVAL IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE PROCTITIS
VEDOLIZUMAB IS ASSOCIATED WITH STEROID-FREE CLINICAL REMISSION AND DISCONTINUATION-FREE SURVIVAL IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE PROCTITIS

EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY
EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

Marc Ferrante  et al.

CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS
CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS

A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES
A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

Marc Ferrante  et al.

EFFECT OF RISANKIZUMAB TREATMENT ON EXTRAINTESTINAL MANIFESTATIONS (EIMS) IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE (CD): RESULTS FROM THE ADVANCE, MOTIVATE AND FORTIFY STUDIES
EFFECT OF RISANKIZUMAB TREATMENT ON EXTRAINTESTINAL MANIFESTATIONS (EIMS) IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE (CD): RESULTS FROM THE ADVANCE, MOTIVATE AND FORTIFY STUDIES

Marc Ferrante  et al.

EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL
EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL

Marc Ferrante  et al.

GENETIC ARCHITECTURE OF FAMILIAL INFLAMMATORY BOWEL DISEASE
GENETIC ARCHITECTURE OF FAMILIAL INFLAMMATORY BOWEL DISEASE

Marc Ferrante  et al.

SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL
SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL

Marc Ferrante  et al.

LONG-TERM EFFECTIVENESS OF DARVADSTROCEL IN PATIENTS WITH COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: RESULTS FROM INSPECT, A RETROSPECTIVE CHART REVIEW STUDY IN EUROPE
LONG-TERM EFFECTIVENESS OF DARVADSTROCEL IN PATIENTS WITH COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: RESULTS FROM INSPECT, A RETROSPECTIVE CHART REVIEW STUDY IN EUROPE

Marc Ferrante  et al.

Item 1 - 20 / 42
1
2 3